O	0	5	Phase
O	6	9	III
O	10	20	randomized
O	21	26	trial
O	27	29	of
B-intervention	30	39	sunitinib
O	40	46	versus
B-control	47	59	capecitabine
O	60	62	in
O	63	71	patients
O	72	76	with
O	77	87	previously
O	88	95	treated
O	96	100	HER2
O	100	101	-
O	101	109	negative
O	110	118	advanced
O	119	125	breast
O	126	132	cancer
O	132	133	.

O	134	138	This
O	139	150	multicenter
O	150	151	,
O	152	162	randomized
O	162	163	,
O	164	168	open
O	168	169	-
O	169	174	label
O	175	180	phase
O	181	184	III
O	185	190	trial
O	191	192	(
O	192	199	planned
O	200	210	enrollment
O	210	211	:
O	212	215	700
O	216	224	patients
O	224	225	)
O	226	229	was
O	230	239	conducted
O	240	242	to
O	243	247	test
O	248	251	the
O	252	262	hypothesis
O	263	267	that
O	268	274	single
O	274	275	-
O	275	280	agent
O	281	290	sunitinib
O	291	299	improves
O	300	311	progression
O	311	312	-
O	312	316	free
O	317	325	survival
O	326	327	(
O	327	330	PFS
O	330	331	)
O	332	340	compared
O	341	345	with
O	346	358	capecitabine
O	359	361	as
O	362	371	treatment
O	372	375	for
O	376	384	advanced
O	385	391	breast
O	392	398	cancer
O	399	400	(
O	400	403	ABC
O	403	404	)
O	404	405	.

B-eligibility	406	414	Patients
I-eligibility	415	419	with
I-eligibility	420	424	HER2
I-eligibility	424	425	-
I-eligibility	425	433	negative
I-eligibility	434	437	ABC
I-eligibility	438	442	that
I-eligibility	443	451	recurred
I-eligibility	452	457	after
I-eligibility	458	471	anthracycline
I-eligibility	472	475	and
I-eligibility	476	482	taxane
I-eligibility	483	490	therapy
O	491	495	were
O	496	506	randomized
O	507	508	(
O	508	509	1
O	509	510	:
O	510	511	1
O	511	512	)
O	513	515	to
O	516	525	sunitinib
O	526	528	37
O	528	529	.
O	529	530	5
O	531	533	mg
O	533	534	/
O	534	537	day
O	538	540	or
O	541	553	capecitabine
O	554	555	1
O	555	556	,
O	556	559	250
O	560	562	mg
O	562	563	/
O	563	564	m
O	564	565	(
O	565	566	2
O	566	567	)
O	568	569	(
O	569	570	1
O	570	571	,
O	571	574	000
O	575	577	mg
O	577	578	/
O	578	579	m
O	579	580	(
O	580	581	2
O	581	582	)
O	583	585	in
O	586	594	patients
B-age	595	596	>
I-age	596	598	65
I-age	599	604	years
O	604	605	)
O	606	609	BID
O	610	612	on
O	613	617	days
O	618	619	1
O	619	620	-
O	620	622	14
O	623	626	q3w
O	626	627	.

O	628	631	The
O	632	643	independent
O	644	648	data
O	648	649	-
O	649	659	monitoring
O	660	669	committee
O	670	671	(
O	671	674	DMC
O	674	675	)
O	676	686	determined
O	687	693	during
O	694	697	the
O	698	703	first
O	704	711	interim
O	712	720	analysis
O	721	722	(
B-intervention-participants	722	725	238
O	726	734	patients
O	735	745	randomized
O	746	748	to
O	749	758	sunitinib
O	758	759	,
B-control-participants	760	763	244
O	764	766	to
O	767	779	capecitabine
O	779	780	)
O	781	785	that
O	786	789	the
O	790	795	trial
O	796	798	be
O	799	809	terminated
O	810	813	due
O	814	816	to
O	817	825	futility
O	826	828	in
O	829	837	reaching
O	838	841	the
O	842	849	primary
O	850	858	endpoint
O	858	859	.

O	860	862	No
O	863	874	statistical
O	875	883	evidence
O	884	893	supported
O	894	897	the
O	898	908	hypothesis
O	909	913	that
O	914	923	sunitinib
O	924	932	improved
O	933	936	PFS
O	937	945	compared
O	946	950	with
O	951	963	capecitabine
O	964	965	(
O	965	968	one
O	968	969	-
O	969	974	sided
O	975	976	P
O	977	978	=
O	979	980	0
O	980	981	.
O	981	984	999
O	984	985	)
O	985	986	.

O	987	990	The
O	991	995	data
O	996	1005	indicated
O	1006	1010	that
B-outcome	1011	1014	PFS
O	1015	1018	was
O	1019	1026	shorter
O	1027	1031	with
O	1032	1041	sunitinib
O	1042	1046	than
O	1047	1059	capecitabine
O	1060	1061	(
O	1061	1067	median
B-iv-cont-median	1068	1069	2
I-iv-cont-median	1069	1070	.
I-iv-cont-median	1070	1071	8
O	1072	1074	vs
O	1074	1075	.
B-cv-cont-median	1076	1077	4
I-cv-cont-median	1077	1078	.
I-cv-cont-median	1078	1079	2
I-cv-cont-median	1080	1086	months
O	1086	1087	,
O	1088	1100	respectively
O	1100	1101	;
O	1102	1104	HR
O	1104	1105	,
O	1106	1107	1
O	1107	1108	.
O	1108	1110	47
O	1110	1111	;
O	1112	1114	95
O	1114	1115	%
O	1116	1118	CI
O	1118	1119	,
O	1120	1121	1
O	1121	1122	.
O	1122	1124	16
O	1124	1125	-
O	1125	1126	1
O	1126	1127	.
O	1127	1129	87
O	1129	1130	;
O	1131	1134	two
O	1134	1135	-
O	1135	1140	sided
O	1141	1142	P
O	1143	1144	=
O	1145	1146	0
O	1146	1147	.
O	1147	1150	002
O	1150	1151	)
O	1151	1152	.

B-outcome	1153	1159	Median
I-outcome	1160	1167	overall
I-outcome	1168	1176	survival
O	1177	1178	(
B-iv-cont-median	1178	1180	15
I-iv-cont-median	1180	1181	.
I-iv-cont-median	1181	1182	3
O	1183	1185	vs
O	1185	1186	.
B-cv-cont-median	1187	1189	24
I-cv-cont-median	1189	1190	.
I-cv-cont-median	1190	1191	6
I-cv-cont-median	1192	1198	months
O	1198	1199	;
O	1200	1202	HR
O	1202	1203	,
O	1204	1205	1
O	1205	1206	.
O	1206	1208	17
O	1208	1209	;
O	1210	1213	two
O	1213	1214	-
O	1214	1219	sided
O	1220	1221	P
O	1222	1223	=
O	1224	1225	0
O	1225	1226	.
O	1226	1229	350
O	1229	1230	)
O	1231	1234	and
B-outcome	1235	1244	objective
I-outcome	1245	1253	response
I-outcome	1254	1259	rates
O	1260	1261	(
B-iv-bin-percent	1261	1263	11
O	1264	1266	vs
O	1266	1267	.
B-cv-bin-percent	1268	1270	16
I-cv-bin-percent	1270	1271	%
O	1271	1272	;
O	1273	1277	odds
O	1278	1283	ratio
O	1283	1284	,
O	1285	1286	0
O	1286	1287	.
O	1287	1289	65
O	1289	1290	;
O	1291	1292	P
O	1293	1294	=
O	1295	1296	0
O	1296	1297	.
O	1297	1300	109
O	1300	1301	)
O	1302	1306	were
O	1307	1318	numerically
O	1319	1327	inferior
O	1328	1332	with
O	1333	1342	sunitinib
O	1343	1349	versus
O	1350	1362	capecitabine
O	1362	1363	.

O	1364	1369	While
O	1370	1372	no
O	1373	1376	new
O	1377	1379	or
O	1380	1390	unexpected
O	1391	1397	safety
O	1398	1406	findings
O	1407	1411	were
O	1412	1420	reported
O	1420	1421	,
O	1422	1431	sunitinib
O	1432	1441	treatment
O	1442	1445	was
O	1446	1456	associated
O	1457	1461	with
O	1462	1468	higher
O	1469	1480	frequencies
O	1481	1484	and
O	1485	1492	greater
O	1493	1503	severities
O	1504	1506	of
O	1507	1511	many
O	1512	1518	common
O	1519	1526	adverse
O	1527	1533	events
O	1534	1535	(
O	1535	1538	AEs
O	1538	1539	)
O	1540	1548	compared
O	1549	1553	with
O	1554	1566	capecitabine
O	1566	1567	,
O	1568	1577	resulting
O	1578	1580	in
O	1581	1585	more
B-outcome	1586	1595	temporary
I-outcome	1596	1612	discontinuations
I-outcome	1613	1616	due
I-outcome	1617	1619	to
I-outcome	1620	1623	AEs
O	1624	1628	with
O	1629	1638	sunitinib
O	1639	1640	(
B-iv-bin-percent	1640	1642	66
O	1643	1645	vs
O	1645	1646	.
B-cv-bin-percent	1647	1649	51
I-cv-bin-percent	1649	1650	%
O	1650	1651	)
O	1651	1652	.

O	1653	1656	The
B-outcome	1657	1665	relative
I-outcome	1666	1670	dose
I-outcome	1671	1680	intensity
O	1681	1684	was
O	1685	1690	lower
O	1691	1695	with
O	1696	1705	sunitinib
O	1706	1710	than
O	1711	1723	capecitabine
O	1724	1725	(
B-iv-bin-percent	1725	1727	73
O	1728	1730	vs
O	1730	1731	.
B-cv-bin-percent	1732	1734	95
I-cv-bin-percent	1734	1735	%
O	1735	1736	)
O	1736	1737	.

O	1738	1743	Based
O	1744	1746	on
O	1747	1752	these
O	1753	1761	efficacy
O	1762	1765	and
O	1766	1772	safety
O	1773	1780	results
O	1780	1781	,
O	1782	1791	sunitinib
O	1792	1798	should
O	1799	1802	not
O	1803	1805	be
O	1806	1810	used
O	1811	1813	as
O	1814	1825	monotherapy
O	1826	1829	for
O	1830	1838	patients
O	1839	1843	with
O	1844	1847	ABC
O	1847	1848	.
